Compugen Beats Q3 Loss Expectations

Compugen Limited, an Israel-based drug developer, reported a net loss of seven million dollars for Q3, surpassing Wall Streets expectations of a nine cents per share loss. Despite the loss, the companys revenue of one point nine million dollars and ability to beat analysts predictions is noteworthy for investors.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.